Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
Sponsor: Mazandaran University of Medical Sciences
Summary
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.
Official title: De-Escalation of Dual Antiplatelet Therapy With Ticagrelor and Aspirin in Non-disabling Non-cardioembolic Ischemic Stroke or High Risk TIA Patients: A Randomized, Outcome Assessor Blind, Controlled Trial
Key Details
Gender
All
Age Range
40 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-04-01
Completion Date
2026-08-01
Last Updated
2025-04-27
Healthy Volunteers
Yes
Conditions
Interventions
Ticagrelor 60 + Aspirin
Ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month and then ticagrelor 60 mg BID plus ASA 80 mg daily until the end of month 6.
Ticagrelor 90 + aspirin
ticagrelor 90 mg BID plus ASA 80 mg daily for 1 month.
Locations (1)
Mazandaran province, Sari,Iran
Sari, Mazandaran, Iran